Michelle Robertson has sold stock and made no open-market buys since Oct 2019

Michelle Robertson is a biopharmaceutical finance executive with over 30 years of financial and commercial operations experience in the life sciences industry.( She has served as Executive Vice President and Chief Financial Officer (EVP, CFO) at Editas Medicine, Inc. (Nasdaq: EDIT), where she was appointed CFO in January 2020 and later held the title EVP, Chief Financial Officer, overseeing finance and capital strategy for the CRISPR genome editing company.( During her tenure at Editas Medicine, she raised approximately $500 million in capital over three years to support the company’s transition into late-stage clinical development.(

Before Editas Medicine, Robertson was Chief Financial Officer of Momenta Pharmaceuticals, Inc. from 2018 to 2020, leading the finance team through a strategic restructuring ahead of the company’s acquisition by Johnson & Johnson.( Her earlier career includes senior finance roles at Baxalta Inc. as Vice President, Oncology Finance following its spin-off from Baxter International Inc., where she worked on the acquisition and commercialization of the oncology drug Oncaspar®, and leadership of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals Inc., supporting the commercial launch of Linzess®.( She spent 16 years at Genzyme Corporation (later acquired by Sanofi) in various finance and commercial operations positions, leading integration of acquired oncology assets and building commercial operations for multiple global products.( In addition to her executive roles, Robertson serves on the board of directors of Verastem Inc., where she is chair of the audit committee.( She holds a B.S. in Finance and an A.S. in Accounting and Management from Bentley University, reflecting a formal academic foundation in finance and accounting.(

Written by Perplexity from public sources.